The Future of Cancer Care
KIYATEC’s goal is to deliver more accurate predictions of patient response to drugs and biologics. We are fulfilling this mission by applying 3D cell-based phenotypic models of cancer with more physiologically relevant tumor microenvironments. By using the patient’s own living tumor cells, these novel diagnostics will serve to better inform clinicians of the best therapeutic candidate to treat that patient’s cancer.
Research efforts have demonstrated our system’s ability to maintain viable 3D tumor tissue in the lab. Additional development efforts have translated laboratory protocols into KIYATEC’s personalized cancer diagnostic currently applied in the second of two blinded biology pilot studies using clinically-derived patient biopsies under IRB approval. These clinically-oriented studies culture the biopsy derived tumor tissue and assess its response to an array of chemotherapy and targeted agents.
The future of cancer care requires advanced diagnostics to assist physicians in actively selecting the most effective therapeutic for each and every patient. Accurate in vitro modeling of an individual’s disease-state requires a degree of complexity that involves multiple cell types and interactions that is currently unmet by traditional “Petri Dish” two-dimensional (2D) cell culture. As a demonstration of this fact, a 2010 study conducted by researchers at Stanford University showed that traditional 2D cell culture models had a 0.0 correlation with the human condition while 3D cell culture models represented a higher human correlation than even mouse models1. This evidence supports KIYATEC’s opportunity to use advanced 3D cell culture techniques in evaluating patient drug response in a personalized fashion.
1 T Ridky, et al. Nature Medicine 2010.